

## Montana Healthcare Programs Prior Authorization Request Form for Use of Kerendia™ (finerenone)

Member Name:	DOB:	Date:
Member ID:	Prescriber Phone:	
Prescriber Name/Specialty if applicable:	Prescriber Fax:	
Dosage Requested:		

*Please complete below information for applicable situation, Initiation or Continuation of therapy:*

### ☐ INITIATION OF THERAPY

1. Member is  $\geq$  18 years of age: ☐ Yes ☐ No
2. Medication is prescribed by or in consultation with a nephrologist: ☐ Yes ☐ No  
**Action Required:** If not in a specialty clinic or written by a specialist, copy of annual specialty consult with an appropriate specialist is required (please attach copy of consult):  
**Name of Specialist:** \_\_\_\_\_ **Contact Date:** \_\_\_\_\_
3. Member is not pregnant: ☐ Yes ☐ No
4. Member has a diagnosis of Chronic Kidney Disease associated with Type II diabetes **AND** an A1C less than 8%: ☐ Yes ☐ No **A1C result:** \_\_\_\_\_ **Date:** \_\_\_\_\_
5. Member has undergone a recent trial (within the past 90 days) of an SGLT2 with the same indication:  
☐ Yes ☐ No **Drug name:** \_\_\_\_\_ **Date:** \_\_\_\_\_
6. Member is currently receiving a maximally tolerated ACE or ARB, unless contraindicated: ☐ Yes ☐ No  
**If No, please provide the reason:** \_\_\_\_\_  
\_\_\_\_\_

7. Prior to the initiation of Kerendia®, member must meet all of the following:
  - a) eGFR is  $\geq$  25ml/min/1.73m<sup>2</sup> and  $<$ 75ml/min/1.73m<sup>2</sup>: ☐ Yes ☐ No  
**Action Required:** Please provide the member's two **most recent** eGFR levels:
    - eGFR result: \_\_\_\_\_ Date: \_\_\_\_\_
    - eGFR result: \_\_\_\_\_ Date: \_\_\_\_\_
  - b) Urine albumin-to-creatinine ratio is  $\geq$  30mg/g: ☐ Yes ☐ No
  - c) Serum potassium level is  $\leq$  5.0mEq/L: ☐ Yes ☐ No

### **LIMITATIONS:**

Maximum dose is 1 tablet daily.

**Initial authorization will be issued for 6 months.**

☐ **CONTINUATION OF THERAPY**

1. Annual specialist consult attached if prescriber is not a specialist: ☐ **Yes** ☐ **No** ☐ **N/A - Prescriber is specialist**
2. Provider has **attached** documentation showing a positive clinical improvement (e.g., eGFR decline has been slowed): ☐ **Yes** ☐ **No** **Most recent eGFR result:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Reauthorization will be issued for 12 months.**

---

**Please complete form, including required attachments, and fax to  
Drug Prior Authorization Unit at 1-800-294-1350.**